Impact of Intrauterine Infusion of Autologous Platelet-Rich Plasma on Assisted Reproductive Outcomes in Patients With Recurrent Implantation Failure: A Meta-Analysis of Randomized Controlled Trials

Why clinicians should know about it

• Picked for Reproductive Medicine (top studies of the week, 19 July 2026).

Abstract

BACKGROUND: This meta-analysis evaluates the efficacy and safety of intrauterine autologous platelet-rich plasma (PRP) infusion in patients with recurrent implantation failure (RIF). METHODS: Following PRISMA guidelines, we systematically searched major databases and included 10 randomized controlled trials (RCTs, n = 1 188). Study quality was assessed using the Cochrane RoB 2.0 tool. RESULTS: PRP infusion significantly improved clinical pregnancy rate (RR = 2.23, 95% CI 1.84-2.69) and live birth rate (RR = 3.74, 95% CI 2.68-5.22) without increasing miscarriage risk. Subgroup analysis indicated that a 0.5 mL PRP volume was as effective as 0.5-1.0 mL, and a notably greater treatment effect was observed in blastocyst transfer cycles compared to cleavage-stage embryo transfers, suggesting potential enhanced benefit in this subgroup. CONCLUSION: Intrauterine PRP infusion is an effective and safe treatment for RIF. The findings on dose equivalence and differential efficacy by embryo stage offer valuable insights for optimizing clinical application.

Abstract as published, via PubMed.